Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNFα antibody therapy

Journal of Clinical Immunology

Volumn 19, Issue 5, 1999, Pages 305-313

  Ohshima, Shiro ^a   Saeki, Yukihiko ^a   Mima, Toru ^b   Sasai, Mitsuko ^a   Nishioka, Katsuhiro ^a   Ishida, Hiroshi ^c   Shimizu, Masatoshi ^b   Suemura, Masaki ^a   McCloskey, Richard ^d   Kishimoto, Tadamitsu ^e  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^c UTANO NATIONAL HOSPITAL   (Japan)

^d CENTOCOR INC   (United States)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

Anti tumor necrosis factor therapy; Cytokine; Lymphocyte; Rheumatoid arthritis

Indexed keywords

AUROTHIOMALATE; AZATHIOPRINE; BETAMETHASONE; BUCILLAMINE; CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CA2; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKINS; LEUKOCYTE COUNT; LEUKOCYTES; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHILS; RECEPTORS, CYTOKINE; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032884288     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020543625282     Document Type: Article

References (48)

1. 1. Panayi GS, Lanchbury JS, Kingsley GH: The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arth Rheum 35:729-735, 1992
2. 2. Mima T, Saeki Y, Ohshima S, et al.: Transfer of rheumatoid arthritis into severe combined immunodeficient mice; The pathogenic implications of T cell populations oligoclonally expanding in the rheumatoid joints. J Clin Invest 96:1746-1758, 1995
3. 3. Feldmann M, Brennan FM, Maini RN: Role of cytokines in autoimmune disease. In Clinical Applications of Cytokines; Role in Pathogenesis, Diagnosis, and Therapy, A Gearing, J Rossio, J Oppenheim (eds). Oxford, Oxford University Press, 1993
4. 4. Arend WP, Drayer JM: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arth Rheum 38:151-160, 1995
5. 5. Miyasaka N, Sato K, Goto M, et al.: Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients possible involvement in joint destruction. Arth Rheum 31:480-486, 1988
6. 6. Duff GW, Dickens E, Wood N, et al.: Immunoassay, bioassay and in situ hybridization of monokines in human arthritis. Prog Leucocyte Bio 8:387, 1988
7. 7. Buchan G, Barrett K, Turner M, et al.: Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis; Prolonged production of IL-1α. Clin Exp Immunol 73:445-449, 1988
8. 8. Chu CQ, Field M, Feldmann M, et al.: Localization of tumor necrosis factor α in synovial tissues and at the cartilage pannus junction in patients with rheumatoid arthritis. Arth Rheum 34: 1125-1132, 1991
9. 9. Field M, Chu CQ, Feldmann M, et al.: IL-6 localization in the synovial membrane in rheumatoid arthritis. Rheumatol Int 11:45-50, 1991
10. 10. Firestein GS, Alvaro Grcia JM, Maki R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144:3347-3353, 1990
11. 11. Tan PL, Farmiloe S, Yeoman S, et al.: Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts. J Rheumatol 17:1608-1612, 1990
12. 12. Wood NC, Symons JA, Dickens E, et al.: In situ hybridization of IL-6 in rheumatoid arthritis. 87:183-189, 1992
13. 13. Lebsack ME, Paul CC, Matindale JJ, et al.: A dose and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis. Arth Rheum 36:s39, 1993
14. 14. Drevlow B, Capezio J, Lovis R, et al.: Phase I study of recombinant human interleukin-1 receptor (RHU IL-R) administered intraarticularly in active rheumatoid arthritis. Arth Rheum 36:s39, 1993
15. 15. Moreland LW, Baumgartner SW, Schiff MH, et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337(3):141-147, 1997
16. 16. Wendling D, Racadot E, Wijdenes J: Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20:259-262, 1993
17. 17. Elliott MJ, Maini RN, Feldmann M, et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arth Rheum 36:1681-1690, 1993
18. 18. Elliott MJ, Maini RN, Feldmann M, et al.: Randomised double blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110, 1994
19. 19. Elliott MJ, Maini RN, Feldmann M, et al.: Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344:1125-1128, 1994
20. 20. Rankin ECC, Choy EHS, Kassimos D, et al.: The therapeutic effects of an engineered human anti-tumor necrosis factor alpha antibody (CD571) in rheumatoid arthritis. Br J Rheumatol 34:334-342, 1995
21. 21. Arnett FC, Edworthy SM, Bloch DA, et al.: The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arth Rheum 31:315-324, 1988
22. 22. Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA 140:659-662, 1949
23. 23. Knight DM, Trinh H, Le J, et al.: Construction and initial characterization of a mouse-human anti-TNFα antibody. Mol Immunol 30:1443-1453, 1993
24. 24. Paulus HE, Egger MJ, Ward JR, Williams HJ: The Cooperative Systematic Studies of Rheumatic Disease Group. Analysis of improved in individual rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs, based on the findings in patients treated with placebo. Arth Rheum 33:477-484, 1990
25. 25. Kobayashi Y, Sawada JI, Osawa T: Activation of membrane phospholipase A by guinea pig lymphotoxin (GLT). J Immunol 122:791-794, 1979
26. 26. Ogata A, Tagoh H, Lee T, et al.: A new highly sensitive immunoassay for cytokins by dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA). J Immunol Methods 148:15-22, 1992
27. 27. Abrams JS, Roncarolo MG, Yssel H, et al.: Strategies of anticytokine monoclonal antibody development; Immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 127:5-24, 1992
28. 28. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN: Deactivation of vascular endothelium by monoclonal antitumor necrosis factor α antibody in rheumatoid arthritis. Arth Rheum 39:1082-1091, 1996
29. 29. Swaak AJ, van Rooyen A, Nieuwenhuis E, et al.: Interleukin 6 (IL-6) in synovial fluid and serum of patients with rheumatic disease. Scand J Rheumatol 17:469-474, 1988
30. 30. Houssiau FA, Devogelaer JP, van Damme J, et al.: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis. Arth Rheum 31:784-788, 1988
31. 31. van Damme J, Opdenakker G, Simpson RJ, et al.: Identification of the human 26-kD protein, interferon b2, as a B cell hybridoma/ plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor. J Exp Med 165:914-919, 1987
32. 32. Dinarello CA, Cannon JG, Wolff SM, et al.: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induced production of interleukin-1. J Exp Med 163:1433-1450, 1986
33. 33. Brenann FM, Chantry D, Jakson A, Maini RN, Feldmann M: Inhibitory effects of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244-247, 1989
34. 34. Butler D, Maini RN, Feldmann M, Brenann FM: Blockade of TNFα with chimeric anti-TNFα monoclonal antibody, cA2 reduces (IL-6 and IL-8) release in RA MNC cultures. A comparison with IL-1ra. Eur Cytokine Netwk 6:225-230, 1995
35. 35. Haworth C, Brenann FM, Chantry D, Turner M, Maini RN, Feldmann M: Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest 83:876-882, 1991
36. 36. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440, 1996
37. 37. Cush TJ, Splawski JB, Thomas R, et al.: Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arth Rheum 38:96-104, 1995
38. 38. Isomaki P, Luukkainen R, Saario R, Toivanen P, Punnonen J: Interleukin-10 functions as an anti-inflammatory cytokine in rheumatoid synovium. Arth Rheum 39:386-395, 1996
39. 39. Mosmann TR: Properties and functions of interleukin-10. Adv Immunol 56:1-26, 1994
40. 40. De Waal Malefyt R, Abrams J, Bennett B, Fidgor CG, de Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209-1220, 1991
41. 41. De Waal Malefyt R, Johnson K, Kastelein R, et al.: Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174:915-924, 1991
42. 42. De Waal Malefyt R, Yssel H, de Vries JE: Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. J Immunol 150:4754-4765, 1993
43. 43. Liblan RS, Singer SM, McDevitt HO: Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune disease. Immunol Today 16:34-38, 1995
44. 44. Cope AP, Londei M, Chu R, et al.: Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; Reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94:749-760, 1994
45. 45. McCall JL, Yun K, Funamoto S, et al.: In vivo immunohistochemical identification of tumor necrosis factor/cachectin in lymphoid tissue. Am J Pathol 135:421-425, 1989
46. 46. de Kossodo S, Gran GE, Daneva T, et al.: Tumor necrosis factor α is involved in mouse growth and lymphoid tissue development. J Exp Med 176:1259-1264, 1992
47. 47. Vella AT, McCormack JE, Linsley PS, et al.: Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity 2:261-270, 1995
48. 48. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J: Chimeric anti-TNFα monoclonal antibody cA2 binds recombinant transmembrane TNFα and activates immune effector functions. Cytokine 7:251-259, 1995